Enhanced Nanocellulose-Derived Hydrogel Systems for Controlled Release of Biologically Active Compounds

This invention relates to novel nanocellulose-derived hydrogel systems with tailored properties for controlled release of biologically active compounds, including insulin, with improved efficacy, safety, and patient compliance.

The original patent disclosed a versatile nanocellulose-derived hydrogel drug delivery system, but it had limitations in terms of diffusion kinetics, protein binding, and release. The new inventive concept addresses these limitations by introducing tailored CNC content, electrostatically charged moieties, and self-assembly of crystalline nanocellulose to provide controlled release of biologically active drug compounds.

The new inventive concept encompasses a range of nanocellulose-derived hydrogel systems with enhanced properties for controlled release of biologically active compounds. These systems include a hydrogel matrix with tailored CNC content to control diffusion kinetics, electrostatically charged moieties to enhance protein binding and release, and self-assembly of crystalline nanocellulose to provide controlled release of a biologically active drug compound. The hydrogel matrix can be further modified to maintain protein structure and prevent aggregation during release, and can be designed for oral delivery, transdermal delivery, or other routes of administration.

The new inventive concept introduces novel and non-obvious features compared to the original patent, including the use of tailored CNC content, electrostatically charged moieties, and self-assembly of crystalline nanocellulose. These features provide a significant improvement in controlled release of biologically active compounds, and are not obvious from the original patent.

Alternative embodiments of the inventive concept include the use of different types of nanocellulose, varying the surface chemistry of the crystalline nanocellulose, and incorporating additional components to enhance bioavailability. Variations of the inventive concept could include the use of different biologically active compounds, such as peptides or vaccines, and the development of hydrogel systems for other routes of administration, such as injectable or implantable systems.

The new inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the development of controlled release systems for insulin and other biologically active compounds. The target market includes patients with chronic diseases, such as diabetes, and caregivers who require convenient and effective drug delivery systems.